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Results The MSI phenomenon was indeed observed in 
ATLLs (4/20, 20%). Intriguingly, the observed microsatel-
lite alterations were invariably Type A, which implies that 
the tumours were MMR-defective. Indeed, clinical out-
comes of patients with these MSI+ tumours were signifi-
cantly worse. Furthermore, multivariate analysis revealed 
that Type A MSI is an independent prognostic factor.
Conclusion These observations strongly suggest the possi-
bility of Type A MSI as a prognostic and potentially predic-
tive biomarker in ATLL.
Keywords Microsatellite instability · DNA 
mismatch repair · Adult T-cell leukaemia/lymphoma · 
Chemotherapy · Drug resistance · Biomarker
Introduction
Adult T-cell leukaemia/lymphoma (ATLL) is a mature 
T-lymphocyte neoplasm with a causative link to retrovi-
ral infection by human T-cell leukaemia virus 1 (HTLV-
1) (Matsuoka and Jeang 2007; Uchiyama 1997; Uchiy-
ama et al. 1977; Verdonck et al. 2007), which is endemic 
in geographically limited areas including south-western 
Japan, sub-Saharan Africa, the Caribbean basin and South 
America (Matsuoka and Jeang 2007; Verdonck et al. 2007). 
HTLV-1-infected populations are estimated to exceed ten 
million around the world. The majority of the infected indi-
viduals however remain asymptomatic throughout their 
lives, and a small subpopulation, less than 5%, develops 
ATLL (Arisawa et al. 2000; Matsuoka and Jeang 2007). 
Among the four clinical subtypes (Shimoyama 1991), acute 
and lymphoma types exhibit an extremely poor patient 
prognosis, primarily because of resistance to antineoplastic 
agents. The median survival time is approximately one year 
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in patients treated with conventional chemotherapy (Tsuka-
saki et al. 2007; Yamada et al. 2001). Although target-based 
therapies using an anti-CCR4 antibody are now regarded as 
promising (Ishida et al. 2012; Yamamoto et al. 2010), allo-
geneic haematopoietic stem cell transplantation (HSCT) 
has been tested during this decade (Hishizawa et al. 2010; 
Jabbour et al. 2011; Okamura et al. 2005; Utsunomiya et al. 
2001), and remission has been reported in some cases. 
These favourable results of HSCT are now discussed in 
connection with graft-versus-host reactions (Kanda et al. 
2012; Yonekura et al. 2008). In addition to factors to modu-
late the host immune response, those leading to an extreme 
drug resistance in tumours also need to be discussed. Bio-
markers to predict response to chemotherapy may be pre-
requisite for personalised approaches to more effective 
treatment of ATLL patients.
Microsatellite instability (MSI), i.e. somatic destabili-
sation of microsatellite DNA sequences comprising short 
reiterated motifs, is regarded as reflecting defective DNA 
mismatch repair (MMR) in tumour cells. MMR is an 
important repair system coupled with DNA replication that 
counteracts replication errors caused by DNA polymerases 
(Jiricny 2006; Modrich 2006). It is now widely known that 
MMR deficiency leads to cellular resistance against various 
antineoplastic agents (Jiricny 2006; Karran 2001), presum-
ably due to avoidance of catastrophic repair reactions on 
the genome. MSI has therefore been regarded as a prom-
ising candidate for a predictive biomarker in the field of 
oncology. Numerous studies have been done to elucidate 
its role in tumour response after chemotherapy, particu-
larly in colorectal cancer patients treated with 5-fluoro-
uracil (5-FU). However, the clinical research data reported 
in the literature lack unity (Guastadisegni et al. 2010), 
whereas 5-FU resistance in MMR-defective cells has been 
established in vitro (Carethers et al. 1999; Tokunaga et al. 
2000a). This may be, at least partly, due to the complexity 
of the MSI phenomenon in colorectal cancer. In this malig-
nancy, microsatellite alterations appear to be comprised of 
several subcategories, depending on the involved micros-
atellite sequences, the repair defects and the tumourigen-
esis pathways. The classification of MSI has in fact been 
controversial. In 1997, the National Cancer Institute (NCI)-
sponsored workshop, ‘Microsatellite Instability and RER 
Phenotypes in Cancer Detection and Familial Predispo-
sition’ (Boland et al. 1998), recommended that the MSI+ 
phenotype should be classified into two different grades, 
i.e. MSI-H (high) (≥20%) and MSI-L (low) (<20%), 
according to the frequencies of changes in a defined set 
of microsatellite markers. This MSI grading established 
by NCI has been widely used since then and, according to 
the MSI grades, the two mutually exclusive pathways have 
been hypothesised in colorectal tumourigenesis. However, 
several reports suggest that this distinction may be an over-
simplification (Goel et al. 2003; Hawkins et al. 2001; Jass 
et al. 2002; Young et al. 2001). In addition, the techniques 
used for microsatellite analyses have been in confusion, 
and several methodological problems are indeed pointed 
out in the conventional assay techniques (Maehara et al. 
2001). We previously established a unique fluorescent tech-
nique in which the major methodological problems are 
overcome (Oda et al. 1997). Application of this technique 
has revealed a number of previously unrecognised aspects 
of MSI in human cancers. In particular, we observed two 
distinct modes of microsatellite alterations, i.e. Type A and 
Type B (Oda et al. 2005). More importantly, we found that 
Type A MSI is the direct consequence of defective MMR, 
and that Type B instability may involve molecular abnor-
malities in addition to the repair defect. The existence of 
these different modes of MSI has shed light on the com-
plexities in the relationship between MMR defects and 
MSI in human cancers, and also in the variety of genomic 
instability underlying tumourigenesis. Thus, the microsatel-
lite stability-based designation of the MMR status appears 
more difficult than hitherto expected.
We have applied our fluorescent technique to vari-
ous human malignancies including colorectal (Ikeda et al. 
2001), endometrial (Eto et al. 2016), gastric (Sakurai et al. 
2007), oesophageal (Araki et al. 2004) and breast (Toku-
naga et al. 2000b) cancers. We have also analysed the 
microsatellite stability in several haematological malig-
nancies using this technique, and found the MSI phenom-
enon in non-Hodgkin lymphoma patients (Miyashita et al. 
2008). Intriguingly, alterations observed in these microsat-
ellite-unstable lymphomas were uniformly Type A, which 
implies that the tumours were MMR-defective (Oda et al. 
2005). Indeed, response to chemotherapy was significantly 
worse in patients with MSI+ tumours, and clinical out-
comes were also less favourable in this population. These 
findings strongly suggest the possibility of MSI as a prog-
nostic and, simultaneously, predictive biomarker in haema-
tological malignancies. Although the predominance of Type 
A MSI in the lymphoma genome is of potential interest in 
connection with lymphomagenesis, the role of MSI merits 
particular attention in the clinical context. In the present 
study, we have applied our fluorescent technique to another 
haematological malignancy, ATLL, in which chemotherapy 
has faced limits and difficulties, and, therefore, predictive 
biomarkers are expected to improve the treatment strate-
gies. Here, we report that Type A MSI is indeed observed 
in tumours arising in ATLL patients, and that this tumour 
phenotype was tightly connected to poor clinical outcomes 
of the patients. Our findings strongly suggest that Type A 
MSI is a prognostic and potentially predictive biomarker in 
ATLL patients.
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Materials and methods
Patients and tissue/cell specimens
Twenty consecutive patients diagnosed as ATLLs and treated 
in the Department of Hematology, National Kyushu Can-
cer Center from 1997 to 2003 were enrolled in this study. 
Patients whose tumour and corresponding normal tissue 
specimens were not available were excluded. Patient char-
acteristics are summarised in Table 1. Men and women were 
fourteen and six, respectively. Age at diagnosis ranged from 
36 to 81 years old, with a mean of 64 years old. The disease 
subtype of each tumour was determined according to Shimoy-
ama criteria of ATLL classification (Shimoyama 1991). All 
the patients had no history of other malignancies that is con-
sistent with genetic predisposition such as Lynch syndrome. 
The majority of the patients received modified EPOCH 
(mEPOCH) initial chemotherapy, in which cyclophosphamide 
is replaced with carboplatin in the classical EPOCH regimen 
(Ishitsuka and Tamura 2014; Wilson et al. 1993), and some 
in combination with intrathecal injection or radiotherapy 
(Table 1). In some elderly patients, the CHOP (Fisher et al. 
1993) or the oral sobuzoxane plus etoposide (PVP) (Kagami 
et al. 1996) therapies were also used. Response to initial treat-
ments was judged according to the International Consensus 
Meeting criteria (Tsukasaki et al. 2009). Tumour tissue speci-
mens were sampled from lymph nodes, skin or other soft tis-
sues. Tumour cells were also collected from peripheral blood 
or bone marrow which contains tumour cells more than 30% 
of total mono-nuclear cell number. Corresponding normal 
tissue specimens were also collected from bone marrow or 
peripheral blood without tumour cells (i.e. less than 10% of 
mono-nuclear cells). Ethical approval was obtained from the 
IRB of National Kyushu Cancer Center. Written informed 
consent for studies was obtained from each patient.
DNA extraction
Tumour specimens were lysed in digestion buffer (10 mM 
Tris–Cl pH 8.0, 0.1 M EDTA pH 8.0, 0.5% SDS, 20 µg/
ml pancreatic RNase). After treatment of proteinase K and 
extraction with phenol, DNA was precipitated with etha-
nol, and then dissolved in 1X TE (10 mM Tris–Cl pH 7.5, 
1 mM EDTA). The concentration of DNA was determined 
by OD260 using a spectrophotometer. The quality of DNA 
was checked by agarose gel electrophoresis. Germline 
DNA was not analysed in this study.
Microsatellite instability
Microsatellite analysis using fluorescence-labelled prim-
ers and an automated DNA sequencer has been described 
in detail (Oda et al. 1997). Briefly, five human dinucleotide 
microsatellites, D2S123, D5S107, D10S197, D11S904 
and D13S175, were amplified by polymerase chain reac-
tion (PCR). Forward primers were labelled with the fluo-
rescent compound, 6-FAM (6-carboxyfluorescein) or HEX 
(6-carboxy-2’,4,4’,5’,7,7’-hexachlorofluorescein). TaKaRa 
Taq (TaKaRa Co. Ltd., Tokyo, Japan) was used as a ther-
mostable polymerase. To compare electrophoretic profiles 
between two samples, 6-FAM-labelled products and HEX-
labelled products were mixed and co-electrophoresed in the 
ABI310 sequencer (Applied Biosystems, Foster City, CA, 
USA). Data were processed using the GeneScan software 
(Applied Biosystems).
MSH2 and MLH1 immunohistochemistry
Tissue specimens were fixed in buffered 10% formalde-
hyde and embedded in paraffin. Prior to the assay, the 
specimens were sectioned at 4 µm and deparaffinised 
using xylene. Immunohistochemistry was performed using 
HISTOFINE SAB-PO(M)/(R) Kit (NICHIREI CORPO-
RATION, Tokyo, Japan). Three independent antibodies 
against MSH2 and MLH1 were used to confirm the results. 
Expression of PCNA was also used as a positive control 
for nuclear staining. Antibodies used were as follows: anti-
MSH2: Ab-1, Ab-2 (Oncogene Research Products, Cam-
bridge, MA, USA) and MSH-2 (BD Biosciences Pharmin-
gen, Hamburg, Germany); anti-MLH1: Ab-1 (Oncogene 
Research Products), MLH-1 (BD Biosciences Pharmingen) 
and C-20 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA); anti-PCNA: PC10 (DakoCytomation California Inc., 
Carpinteria, CA, USA); non-specific IgG: X931 and X936 
(DakoCytomation California Inc.).
Statistical analysis
The cumulative survival curves were plotted using the 
Kaplan–Meier method and compared using the log rank 
method. To determine the significance of each clinico-
pathological variable as a prognostic factor, univariate and 
multivariate analyses were done using Cox proportional 
hazards models. All statistical calculations were done using 
the SAS software version 9.3 (SAS Institute, Cary, NC, 
USA).
Results
Detection of microsatellite instability in adult 
T‑cell leukaemia/lymphoma using High‑Resolution 
Fluorescent Microsatellite Analysis (HRFMA)
We have applied our unique fluorescent technique, HRFMA, 
for MSI analysis in a panel of 20 ATLL patients (Table 1). 
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Unequivocal alterations in microsatellite sequences were 
found in four tumours, and are shown in Fig. 1. In three of 
the four tumours, microsatellite alterations were noted in one 
of the five markers examined (Table 1), which implies that 
their phenotypes are classified as MSI-L, according to the 
NCI criteria (Boland et al. 1998). From another viewpoint, all 
the observed alterations are categorised as Type A, because 
the length changes were all within 6-bp (see “Discussion”). 
More drastic alterations categorised as Type B were not found 
in this panel. In DNA fragment analyses using a fluorescent 
system, loss of heterozygosity (LOH) is also detectable, but 
some patterns of peak clusters are theoretically indistinguish-
able between Type A MSI and LOH (Fujii et al. 2009). We 
have designated these peak patters as LOH’. Indeed, LOH’ 
was observed in several tumours in this panel (Table 1). These 
tumours were therefore not scored as MSI+, which may lead 
to an underscoring of microsatellite-unstable tumours. Une-
quivocal LOH was also observed in six tumours of the panel 
(30%) (Table 1). The above results were highly reproducible 
in several independent experiments, and thus the overall MSI 
frequency was determined as 20%.
It is widely known that MSI is often caused by promoter 
methylation of an essential MMR gene, MLH1, particularly 
in sporadic colorectal carcinomas (Herman et al. 1998). 
Therefore, we next examined expression of MLH1 in the 
tumours of the panel, using immunohistochemistry. Loss of 
MLH1 expression was however observed in none of those 
including four MSI+ tumours (Fig. 2). This observation is 
consistent with the results previously reported in the lit-
erature that MLH1 silencing by promoter methylations is 
very infrequent in ATLL tumours (Matsushita et al. 2005). 
Expression of MSH2, another essential MMR gene, was 
also examined, but no alterations were found (Fig. 2).
Poor clinical outcomes in adult T‑cell leukaemia/
lymphoma patients with MSI+ tumours
Although HSCT (Jabbour et al. 2011) and target-based 
therapies (Ishida et al. 2012; Yamamoto et al. 2010) are now 
regarded as promising, antineoplastic agents still play a 
major role in the treatment of ATLL patients (Ishitsuka and 
Tamura 2014; Tsukasaki and Tobinai 2014; Utsunomiya 
Fig. 1  Microsatellite instability observed in adult T-cell leukaemia/
lymphoma. The amount of each DNA fragment is quantitatively 
detected and its size is standardised with an accuracy of one base 
pair, using co-electrophoresed size markers. Results representative for 
MSI are shown: red lines, tumour; green lines, normal control. All the 
microsatellite changes observed were Type A: a ATL01; b ATL07; c 
ATL09; d and e ATL16. These patient codes correspond to those in 
Table 1
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et al. 2015). As mentioned above, MMR deficiency causes 
cellular resistance against various antineoplastic agents 
such as cyclophosphamide, doxorubicin (Drummond 
et al. 1996; Fink et al. 1998) and etoposide (Aebi et al. 
1997; Fink et al. 1998). Since these agents are used in the 
chemotherapy against ATLL, drug resistance and subse-
quent poor patient prognosis due to defective MMR are 
of particular interest. Therefore, clinical outcomes were 
compared between in patients with Type A MSI+ tumours 
and in those without the tumour phenotype. The clinico-
pathological variables, including age, gender, subtype, Ann 
Arbor stage, Eastern Cooperative Oncology Group per-
formance status (PS), serum LDH and calcium and num-
ber of lesions, were not significantly different between 
the two groups (data not shown) (see Table 1). Cumula-
tive overall survival for the patients was then determined 
using the Kaplan–Meier method (Fig. 3). As expected, the 
patient survival was significantly worse in the MSI+ group 
(p = 0.041), and all the four patients succumbed to the dis-
ease within four years. Similar results were obtained also 
in the patient survival before HSCT (p = 0.048, data not 
shown). We next examined whether MSI is an independent 
prognostic factor. In univariate analyses, p values were 
calculated in each clinicopathological variables, and those 
for age, PS and MSI were 0.067, 0.058 and 0.054, respec-
tively (Table 2). Finally, multivariate analysis revealed that 
age (p = 0.030) and MSI (p = 0.019) are an independent 
prognostic factor, although, due to the paucity of subjects 
and events, the 95% confidence interval was broad. Thus, 
we conclude that Type A MSI is an independent prognostic 
factor in ATLL patients.
Discussion
To date, MSI in ATLL has been addressed by several 
groups (Table 3). The first report of microsatellite-unsta-
ble ATLLs appeared in the literature in 1998 (Hatta et al. 
1998). In this report, Hatta et al. observed the MSI phe-
nomenon in ten out of 22 tumours of their panel (45%), 
and the observed phenotypes were all MSI-L. In another 
early report, Hayami et al. (Hayami et al. 1999) found eight 
microsatellite-unstable tumours in 18 patients (44%), and 
the frequencies for MSI-H and -L were both 22%. In these 
two studies, authentic mono- and dinucleotide microsatel-
lite sequences were analysed using autoradiography tech-
niques. On the other hand, the other reports focused genes 
that carry microsatellite-like repetitive motifs, i.e. mono-
nucleotide runs, in their ORFs, such as TGFBR2, IGF2R, 
BAX, E2F4, MSH3, CASP5, TCF4 and PTEN. This may 
be based on the widely accepted viewpoint that destabili-
sation of the intragenic mononucleotide runs is frequently 
observed in microsatellite-unstable tumours, particularly 
in colorectal carcinomas (Schwartz et al. 1999). However, 
instability of these genes is exclusively associated with the 
Fig. 2  MSH2 and MLH1 immunohistochemistry in MSI+ ATLLs. 
Expressions of MSH2 and MLH1 in the MSI+ tumours were exam-
ined by immunohistochemistry using three independent antibod-
ies. Representative results are shown (patient ATL01 and ATL16). 
No abnormal expression of these proteins was observed in all MSI+ 
ATLLs
Fig. 3  Overall survival of ATLL patients with/without MSI. Cumula-
tive overall survival for each group was obtained using the Kaplan–
Meier method
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MSI-H phenotype and is very rare in MSI-L or microsat-
ellite-stable (MSS) tumours. This is one reasoning for the 
two mutually exclusive pathways in colorectal tumouri-
genesis (Lengauer et al. 1998; Perucho 1996). Indeed, 
alterations in the repeat-including genes were infrequent in 
ATLLs. Ohshima et al. (Ohshima et al. 2000) observed no 
mutations in these genes, whereas Komatsu et al. (Komatsu 
et al. 2000) reported alterations only in E2F4 (2/10, 20%) 
and Takeuchi et al. (Takeuchi et al. 2003) found TCF4 and 
PTEN mutations in cell lines. These previous observations 
in the literature may suggest that the MSI phenomenon is 
indeed observable in ATLLs, and that the MSI-L phenotype 
may predominate in them. One problem in the first two 
studies is that the techniques used were gel electrophoresis 
and autoradiography. In gel electrophoresis, the migration 
of DNA fragments is error-susceptible and sometimes mis-
read, which will lead to scoring of false positives. Because 
autoradiography has biased (i.e. non-linear) detection char-
acteristics, the signal of each band is often misestimated 
and sometimes not detected, which leads to scoring of false 
negatives. Currently, fluorescent systems using automated 
DNA sequencers are instead used and prevalent worldwide. 
We have first applied a fluorescent system for analysing 
classical intergenic microsatellites in ATLL. Indeed, the 
assay techniques used for MSI analyses have been in confu-
sion, and several methodological problems are pointed out 
in them (Maehara et al. 2001). Application of fluorescent 
systems has remarkably improved the above-mentioned 
problem in the detection characteristics. We further added 
dual colour co-electrophoresis to our fluorescent system, in 
order to completely exclude migration errors. In this sys-
tem, two differentially labelled PCR products, derived from 
tumour (red) and the corresponding normal tissues (green), 
are co-electrophoresed (see Fig. 1). In addition to the prob-
lems in the migration and the detection of DNA fragments, 
the post-synthetic modification of PCR products by ther-
mostable DNA polymerases is also pointed out (Maehara 
et al. 2001). We therefore employed the enzymatic treat-
ment or the primer sequence modification, in order to sim-
plify electrophoretic profiles of PCR products and conse-
quently to improve the reproducibility of results. Thus, the 
major methodological problems are overcome in our fluo-
rescent system, HRFMA. Compared with recently tested 
genome-wide approaches using next-generation sequencers 
(NGS) (Lu et al. 2013), one disadvantage of PCR-based 
approaches may be that a very limited number of micro-
satellites are assayed, and that, therefore, their selection 
is critical. We have selected five sensitive dinucleotide 
Table 2  Univariate and 
multivariate analyses of 
prognostic factors in ATLL 
patients
A acute type, CI confidence interval, HR hazard ratio, L lymphoma type, MSI microsatellite instability, PS 
Eastern Cooperative Oncology Group performance status, Stage Ann Arbor stage
Variable Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
MSI 3.296 (0.979–11.092) 0.054 5.460 (1.327–22.465) 0.019
Age 1.063 (0.996–1.134) 0.067 1.093 (1.009–1.183) 0.030
Gender (female vs. male) 0.326 (0.071–1.494) 0.149
Subtype (A vs. L) 0.460 (0.124–1.704) 0.245
Stage 1.165 (0.530–2.563) 0.703
PS (2–4 vs. 0–1) 7.266 (0.933–56.560) 0.058
Hypercalcaemia 1.249 (0.392–3.981) 0.707
Table 3  Microsatellite instability in ATLL: reports in the literature
di- dinucleotide microsatellites, F fluorescence, LN lymph nodes, mono- mononucleotide microsatellites, MSI microsatellite instability, NE not 
evaluated, PB peripheral blood, R autoradiography, Seq sequencing, tetra- tetranucleotide microsatellites, tri- trinucleotide microsatellites, %H 
MSI-H (high), %L MSI-L (low)
Author Year No.  
of cases
Subject Locus No. of 
loci
Detection MSI
Tumour Control %MSI %H %L
Hatta et al. 1998 22 Unknown PB di- 54 R 45 0 45
Hayami et al. 1999 18 PB or LN Hair root mono-/di-/tri-/tetra- 6 R 44 22 22
Ohshima et al. 2000 10 Unknown Placenta TGFBR2, IGF2R, BAX 3 F 0 0 0
Komatsu et al. 2000 10
(all MSI +)
Unknown – TGFBR2, IGF2R,  
BAX, E2F4, MSH3
5 Seq – – –
Takeuchi et al. 2003 11 Cell line – mono- 1 R 18 18 NE
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microsatellites located in five independent chromosomes 
that are readily destabilised in MMR-defective cells (Oki 
et al. 1999). We have first applied this unique assay tech-
nique for MSI analyses of ATLLs, and the obtained fre-
quency of MSI was 20%.
One important finding of this study is that Type A MSI 
predominates in ATLLs. This may be consistent with the 
above discussion that the MSI-L phenotype may be predom-
inant in ATLLs, since in colorectal cancer Type A instability 
tends to be observed in a limited number of markers and, 
therefore, categorised as MSI-L (Ikeda et al. 2001). Indeed, 
the majority of the observed microsatellite alterations were 
noted in one marker (see Table 1). In other words, the 
MSI-L phenotype was predominant. Nevertheless, the mode 
of microsatellite alterations appears more important than 
the frequency of changes, because the relationship between 
the mode and defective MMR has been approached in our 
previous study. Type A MSI is defined a relatively small 
change within 6-bp in dinucleotide microsatellites (i.e. 3 
repeat units), and Type B as a more extensive microsatellite 
change involving ≥ 8-bp (i.e. ≥ 4 repeat units) (Oda et al. 
2005). In addition, repeat length alterations in Type B MSI 
are sometimes discontinuous and, therefore, appear as if a 
‘third’ allele is present in addition to the parental alleles. 
Intriguingly, the microsatellite changes observed in cells of 
MMR gene-knockout mice and tumours occurring in the 
animals were invariably Type A, and there was no evidence 
of the emergence of Type B alterations in the MMR-defec-
tive animals (Oda et al. 2005). These observations strongly 
suggest that defective MMR is necessary and sufficient for 
Type A instability and that, in other words, Type A MSI is a 
direct consequence of MMR deficiency. On the other hand, 
MMR defects may be insufficient for the development of 
more drastic Type B alterations, and molecular abnormali-
ties in addition to repair deficiency may contribute to, or be 
responsible for, Type B MSI. Although Type B instability 
is widely observed in human tumours including the classi-
cal examples in hereditary non-polyposis colorectal cancer 
(HNPCC) (alias Lynch syndrome, LS), previously unrec-
ognised molecular abnormalities may underlie tumourigen-
esis in this category of human neoplasms. Thus, we dem-
onstrated that Type A instability reflects MMR-defective 
phenotypes in tumour cells. The presence of Type A MSI in 
ATLLs strongly suggests that MMR deficiency does occur 
in this malignancy, and that some ATLLs do exhibit the 
MMR-defective phenotypes.
Another important phenotype of MMR-defective cells is 
drug resistance. Connection between MMR defects and cel-
lular resistance to anticancer drugs has initially been pointed 
out by Karran and colleagues (Branch et al. 1993) in 1993. 
They have shown that cells defective of MMR are highly 
resistant to mono-functional alkylating agents. Detailed 
mechanism of drug resistance in repair-deficient cells is still 
not well understood. It has however been established that a 
form of methylated guanine bases, i.e. O6-methylguanine 
(O6meG), can pair not only with cytosine but also with thy-
mine, and that the thymine–guanine base mismatch stimu-
lates cellular MMR (Karran 2001). The genome-wide acti-
vation of MMR may lead to catastrophic repair reactions on 
the genome, and, consequently, to cell death. Resistance of 
MMR-defective cells to 6-thioguanine (6-TG) or 6-mercap-
topurine (6-MP) is similarly explained (Swann et al. 1996). 
Various antineoplastic agents, including 5-FU (Aebi et al. 
1997; Carethers et al. 1999; Tokunaga et al. 2000a), cispl-
atin (Aebi et al. 1996; Anthoney et al. 1996; Drummond 
et al. 1996), camptothecin, etoposide (Aebi et al. 1997; Fink 
et al. 1998) and anthracyclines (Drummond et al. 1996; Fink 
et al. 1998), have been tested since then, and, in some, their 
effects have been shown to be modulated by cellular MMR 
activities. In particular, the connection between MMR and 
5-FU has attracted attention, since 5-FU is one of the most 
widely used antineoplastic agents in cancer chemotherapy. It 
has been demonstrated by several groups that MMR-defec-
tive cells are resistant to 5-FU in vitro (Carethers et al. 1999; 
Tokunaga et al. 2000a), although detailed mechanisms of the 
resistance are still unknown. This hypothesis, however, has 
not been verified in the clinical setting. In order to elucidate 
the connection between defective MMR and tumour resist-
ance to 5-FU, numerous clinical studies have been done, 
particularly in colorectal cancer patients treated with 5-FU-
based post operative adjuvant chemotherapies. However, the 
data reported in the literature are inconsistent and, therefore, 
still not conclusive (Guastadisegni et al. 2010). In addition 
to the complexity of the clinical outcomes of patients, the 
heterogeneity of the MSI phenomenon in colorectal cancer 
may, at least partly, contribute to the discrepancy between the 
in vitro and the in vivo data, since the MSI phenomenon has 
been uniformly regarded as a hallmark of MMR defects. The 
absence of Type B MSI in ATLLs may indicate that the rela-
tionship between repair defects and the MSI phenomenon is 
straightforward in this malignancy, and that, in other words, 
ATLLs exhibiting MSI (i.e. Type A) can be straightforwardly 
regarded as MMR-defective. Indeed, patient outcomes were 
significantly worse in MSI+ ATLLs, which may be because 
the tumours had the drug-resistant MMR-defective pheno-
types, and chemotherapy was not effective in these patients. 
Furthermore, we first demonstrated that MSI is an independ-
ent prognostic factor in ATLL, although statistical power was 
limited because of the paucity of subjects and events. These 
observations strongly support the possibility that Type A MSI 
is a prognostic and potentially predictive biomarker in ATLL 
patients, because their clinical outcomes are largely depend-
ent on the results of initial chemotherapy. Thus, in contrast to 
colorectal cancer, the simplicity of the MSI phenomenon in 
this malignancy may have led to a more straightforward con-
nection between MSI and drug resistance. Although HSCT 
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and the anti-CCR4 therapy are widely tested, these modali-
ties are used as a second-line treatment, and chemotherapy 
using antineoplastic agents still plays a major role and is the 
first line in the treatment of ATLL patients (Ishitsuka and 
Tamura 2014; Tsukasaki and Tobinai 2014; Utsunomiya et al. 
2015). However, there are in fact some tumours that exhibit a 
remarkable resistance to chemotherapy, as exemplified in the 
MSI+ cases in this study. Biomarkers predicting the tumour 
sensitivity to antineoplastic agents are of particular impor-
tance and use. The Type A MSI phenotype of ATLLs may 
provide critical information in the treatment strategies. Need-
less to say, before concluding this, it is necessary to test the 
hypothesis in a larger cohort, in order to confirm and general-
ise the results of this study. Propagation of precise assay tech-
niques is also necessary, because Type A alterations are minor 
and more subtle than the widely acknowledged mode of 
microsatellites changes (i.e. Type B MSI) and obviously dif-
ficult to be detected by less sensitive techniques. These efforts 
may lead to the establishment of reliable predictive biomark-
ers and, consequently, to truly personalised approaches for 
more effective treatment of ATLL patients.
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